These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29371686)

  • 1. Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Coltoff A; Lancman G; Kim S; Steinberg A
    Bone Marrow Transplant; 2018 Jul; 53(7):900-904. PubMed ID: 29371686
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
    Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review].
    Gao SC; Feng YM; Gao L; Kong PY; Zhu LD; Liu J; Wang L; Liu HF; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1046-1049. PubMed ID: 36709113
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
    Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient.
    Pai V; Abu-Arja R; Auletta JJ; Rangarajan HG
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28298. PubMed ID: 32472970
    [No Abstract]   [Full Text] [Related]  

  • 7. Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients.
    Tao T; Ma X; Yang J; Zou JY; Ji SM; Tan YS; Gong W; Du F; Xu J; Ye CM; Tang XW; Wu DP; Xue SL
    Blood Cancer J; 2015 Apr; 5(4):e308. PubMed ID: 25885428
    [No Abstract]   [Full Text] [Related]  

  • 8. The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model.
    Palaniyandi S; Kumari R; Strattan E; Huang T; Du J; Hakim N; Kesler MV; Hildebrandt GC
    Am J Hematol; 2020 Feb; 95(2):E39-E41. PubMed ID: 31724186
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6.
    Kolb M; Bhatia M; Madina GG; Satwani P
    Pediatr Blood Cancer; 2015 Feb; 62(2):362-363. PubMed ID: 25212196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
    Hedin C; Halfvarson J
    Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD).
    Carella AM; Beltrami G; Scalzulli PR; Carella AM; Corsetti MT
    Bone Marrow Transplant; 2004 Jan; 33(1):131-2. PubMed ID: 14566330
    [No Abstract]   [Full Text] [Related]  

  • 12. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis.
    Kim HP; Reed CC; Herfarth HH; Dellon ES
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1992-1994. PubMed ID: 29596982
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab for steroid refractory acute graft-versus-host disease.
    Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
    Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons Learned from Early Experiences with Vedolizumab for Steroid-Refractory Acute Graft- versus-Host Disease with Gastrointestinal Involvement.
    Bukauskas A; Griskevicius L; Peceliunas V
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1597. PubMed ID: 28578009
    [No Abstract]   [Full Text] [Related]  

  • 17. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
    Wright AP; Fontana RJ; Stidham RW
    Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of integrin expression in the prediction of response to vedolizumab: A prospective real-life multicentre cohort study.
    De Galan C; Gonzales GB; Van Welden S; Tavernier SJ; Lobaton T; Van Moerkercke W; Strubbe B; Peeters H; Macken E; De Vos M; Laukens D; Hindryckx P
    Clin Transl Med; 2022 Apr; 12(4):e769. PubMed ID: 35384344
    [No Abstract]   [Full Text] [Related]  

  • 20. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.
    Cushing KC; Mino-Kenudson M; Garber J; Lochhead P; Khalili H
    Am J Gastroenterol; 2018 Apr; 113(4):632-633. PubMed ID: 29610507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.